Braasch Biotech LLC

Discussion in 'Men's Economics' started by Michael Scally MD, Sep 28, 2012.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Braasch Biotech LLC
    Braasch Biotech LLC

    Braasch Biotech LLC is a privately held, preclinical stage Vaccine Company that specializes in the discovery, early stage development and commercialization of an exciting new class of biopharmaceutical vaccine products for the human and animal healthcare market. Our Cross Platform Utilization of Vaccination (CPUV™) is a paradigm shift in the field of Vaccinology

    After several years of successful foundational science, development and intellectual property generation, the company is now ready to advance to a critical monetization stage of its lifecycle. We have recently completed key proof-of-concept testing and intellectual property activities and are now actively developing a diversified pipeline of second-generation somatostatin-based immunopharmaceutical vaccines for humans and animals.

    Braasch's platform technology has significant opportunities to create a large pipeline of new products. Delivering new treatments, categories and segments for innovative Growth Hormone ("GH") and Insulin-like Growth Factor -1 ("igf-1") treatment alternatives which address some of the highest valued markets available in medicine.
     
  2. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Haffer KN. Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice. J Anim Sci Biotechnol 2012;3(1):21. Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice

    The purpose of the study was to test the therapeutic effects of novel vaccines for reducing weight gain and increasing weight loss in diet induced obesity (DIO) model. Male C57BL/6 J mice, fed a 60% Kcal fat diet for 8 weeks prior to the start of the study, were vaccinated via the intraperitoneal route with two formulations (JH17 & JH18) of chimeric-somatostatin vaccines at 1 and 22 days of the study. Control mice were injected with PBS. All mice continued to be feed the 60% Kcal fat diet for the 6 week study. Body weights were measured two times a week and food intake was measured weekly. At week 6, mice were euthanized and a terminal bleed was made and antibody levels to somatostatin and levels of insulin-like growth factor 1 (igf-1) were determined.

    Vaccination with both vaccine formulations induced a statistically significant body weight change over the study period, as compared with PBS controls. Percentage of baseline body weight was also significantly affected by vaccination during the study period. Vaccinates finished the study at 104% and 107% of baseline weight, JH17 & JH18 respectively, while untreated controls reached 115% of baseline weight. Food intake per mouse was similar in all mouse groups during the entire study. Control mice did not demonstrate any antibody titers to somatostatin, while all vaccinated mice had measurable antibody responses (> 1:500,000 titer). IGF-1 levels were not statistically significant among the groups, but were elevated in the JH18 vaccinates (mean 440.4 ng/mL) when compared with PBS controls (mean 365.6 ng/mL).

    Vaccination with either JH17 or JH18 chimeric -somatostatin vaccines produced a statistically significant weight loss as compared with PBS controls (P < 0.0001), even though the DIO mice with continually fed a 60% Kcal fat diet. The weight loss/lower weight gain observations were even more significant, as all mice consumed similar amounts of food for the entire study. The presence of high levels of anti-somatostatin antibodies at 6 weeks was correlative with the weight observations and confirmed the success of vaccination.